
Biophytis SA BPTS
Geschäftsbericht 2023
hinzugefügt 27.12.2025
Biophytis SA Langfristige Verbindlichkeiten 2011-2026 | BPTS
Langfristige Verbindlichkeiten Jährlich Biophytis SA
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 2.02 M | 5.54 M | 6.57 M | 822 K | 961 K | 428 K | 562 K | 344 K | 319 K | - |
Alle Zahlen in EUR-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 6.57 M | 319 K | 1.95 M |
Langfristige Verbindlichkeiten Vierteljährlich Biophytis SA
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 7.41 M | - | - | - | 2.02 M | - | - | - | 5.54 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in EUR-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 7.41 M | 2.02 M | 4.99 M |
Langfristige Verbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
79.1 K | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M | ||
|
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
131 M | - | - | $ 866 M | ||
|
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
184 M | - | 2.54 % | $ 160 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
383 M | $ 0.8 | -3.61 % | $ 36.6 M | ||
|
Exelixis
EXEL
|
63.6 M | $ 46.17 | -5.2 % | $ 12.5 B | ||
|
Athira Pharma
ATHA
|
876 K | - | - | $ 269 M | ||
|
Fortress Biotech
FBIO
|
83.9 M | $ 2.42 | -4.9 % | $ 67.5 M | ||
|
Heron Therapeutics
HRTX
|
14.6 M | $ 1.23 | -6.11 % | $ 205 M | ||
|
Ionis Pharmaceuticals
IONS
|
1.28 B | $ 75.65 | -1.56 % | $ 12.1 B | ||
|
BioNTech SE
BNTX
|
341 M | $ 92.69 | -2.7 % | $ 27.2 B | ||
|
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
711 M | $ 208.55 | -10.32 % | $ 3.81 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
49.6 M | - | - | $ 3.73 B | ||
|
Mirum Pharmaceuticals
MIRM
|
50.3 M | $ 104.1 | -5.43 % | $ 5.23 B | ||
|
MannKind Corporation
MNKD
|
219 M | $ 3.53 | -0.98 % | $ 1.08 B | ||
|
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | ||
|
Esperion Therapeutics
ESPR
|
355 M | $ 3.15 | - | $ 655 M | ||
|
Matinas BioPharma Holdings
MTNB
|
915 K | $ 0.64 | -6.49 % | $ 3.5 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
1.19 M | - | - | $ 5.93 M | ||
|
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M | ||
|
Nanobiotix S.A.
NBTX
|
44.5 M | $ 43.39 | 3.64 % | $ 286 B | ||
|
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | ||
|
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | ||
|
Aptose Biosciences
APTO
|
27.9 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
114 K | - | -39.0 % | $ 4.57 M | ||
|
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
79.1 M | - | -0.23 % | $ 916 M | ||
|
Allakos
ALLK
|
8.11 M | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
5.46 M | - | 4.14 % | $ 49.1 M | ||
|
Arcutis Biotherapeutics
ARQT
|
167 M | $ 20.68 | -14.46 % | $ 2.63 B | ||
|
Allena Pharmaceuticals
ALNA
|
10.2 M | - | 3.16 % | $ 1.9 M | ||
|
Genmab A/S
GMAB
|
769 M | $ 27.08 | -2.9 % | $ 16.7 B | ||
|
Ampio Pharmaceuticals
AMPE
|
3.53 M | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
106 M | - | - | $ 10.1 M | ||
|
Alpine Immune Sciences
ALPN
|
15.9 M | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
4.59 M | - | 10.36 % | $ 9.8 M | ||
|
Applied Therapeutics
APLT
|
797 K | - | - | $ 8.42 M | ||
|
Aravive
ARAV
|
10.2 M | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
854 K | - | 17.91 % | $ 11.1 M |